Shares of AstraZeneca PLC (NYSE:AZN) have been assigned a consensus rating of “Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $83.80.
A number of equities analysts have recently issued reports on AZN shares. Morgan Stanley upgraded AstraZeneca from an “equal weight” rating to an “overweight” rating in a research report on Monday, December 7th. UBS Group reiterated a “positive” rating on shares of AstraZeneca in a report on Monday, December 14th. Piper Sandler lowered their target price on AstraZeneca from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Sunday, December 13th. HSBC upgraded AstraZeneca from a “reduce” rating to a “hold” rating in a report on Wednesday, November 11th. Finally, Oddo Bhf upgraded AstraZeneca from a “reduce” rating to a “buy” rating in a report on Wednesday, September 23rd.
Shares of AZN opened at $49.99 on Wednesday. AstraZeneca has a 1 year low of $36.15 and a 1 year high of $64.94. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.82 and a quick ratio of 0.63. The company has a market capitalization of $131.20 billion, a price-to-earnings ratio of 60.23, a price-to-earnings-growth ratio of 1.63 and a beta of 0.50. The business has a 50-day moving average of $52.65 and a 200-day moving average of $54.14.
AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Tuesday, November 10th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.03. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. The company had revenue of $6.58 billion during the quarter, compared to the consensus estimate of $6.65 billion. During the same period last year, the company earned $0.99 earnings per share. The firm’s revenue was up 7.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that AstraZeneca will post 2.03 EPS for the current year.
Institutional investors have recently made changes to their positions in the business. Johnson Financial Group Inc. acquired a new stake in AstraZeneca in the third quarter valued at approximately $26,000. Clear Harbor Asset Management LLC purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $27,000. Simon Quick Advisors LLC purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $30,000. HM Payson & Co. purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $30,000. Finally, Adams Wealth Management purchased a new position in shares of AstraZeneca during the third quarter valued at approximately $30,000. 16.30% of the stock is owned by hedge funds and other institutional investors.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases.
Further Reading: What is Net Asset Value (NAV)?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.